乙型肝炎病毒复制阳性417例的ALT、乙肝标志物和HBV DNA临床分析

目的调查417例乙型肝炎病毒复制阳性患者的肝损伤、乙肝标志物（HBV Markers．HBVM）和外周血HBV DNA水平及抗病毒治疗适应证符合情况。方法对乙型肝炎病毒复制阳性的417例患者的ALT、乙肝标志物（5项）和HBV DNA进行定量分析。结果HBV DNA阳性者中，性别间ALT各组例数比例不同，但在ALT≥2ULN组．性别间ALT例数相同，而HBV DNA拷贝数差异有统计学意义。ALT各组的HBeAg阴、阳性分布无差异．ALT各组HBV DNA拷贝数随ALT升高而升高。乙肝标志物组的13、145、15组的抗病毒治疗适应证符合率是一致的．135组高于其他三组，且13、135组HBV DNA拷贝数无差异，高于其他两组。结论监测ALT、乙肝标志物和HBV DNA，有助于了解本地区HBV感染情况，节约医疗资源，及时治疗，延缓病程。

Clinical Analysis for ALT,HBV Markers and HBV DNA of 417 HBV-DNA- positive Cases

Objective To investigate the status of liver damage, HBV markers （ HBVM ） and HBV DNA level in peripheral blood and the selection of 417 HBV-DNA-positive patients for treatment. Methods The outcomes of alanihe aminotransferase （ALT） , HBVM （5 items） and HBV DNA together were statistically analyzed for 417 HBV-DNA-positive eases. Results In HBV-DNA- positive eases, the frequencies of ALT were different between sexes, but in those with ALT ≥ 2ULN they were. the same. The rates of HBeAg-positivc cases in all the ALT groups were not different, and the level of HBV DNA increased with elevation of ALT. The rate of selection for treatment of HBVM-13, -145 and -15 groups was the same, and that of HBVM-135 group was higher than that of the other three ones. The level of HBV DNA between group HBVM-135 and -13 was not different, and higher than that of the other two. Conclusion Monitoring ALT, HBVM and HBV DNA is helpful to the assessment for the status of local HBV infection, the effective use of medical resource, and therefore the performance of treatment in time or the postponement of disease development.